RPGLIFERPG Life Sciences Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Profit growth: 17.0% YoY
- • ROE: 19.0%
- • ROCE: 20.3%
- • MACD: bullish
- • Price vs EMA21: above
- • Price vs SMA200: above
- • Pullback to 21-EMA signal (setup quality 65%)
Bull case
- • Profit growth: 17.0% YoY
- • ROE: 19.0%
- • ROCE: 20.3%
- • MACD: bullish
Bear case
- • Price vs SMA50: below
- • 1-month return: -4.7%
- • Volume trend: 0.8x baseline
- • Beta: -0.20
Key risks
- • Price vs SMA50: below
- • 1-month return: -4.7%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹112.01). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.